Authors: Rudin, CM Holmlund, J Fleming, GF Mani, S Stadler, WM Schumm, P Monia, BP Johnston, JF Geary, R Yu, RZ Kwoh, TJ Dorr, FA Ratain, MJ

Citation: Cm. Rudin et al., Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer, CLIN CANC R, 7(5), 2001, pp. 1214-1220

Authors: Gao, Q Tomlinson, G Das, S Cummings, S Sveen, L Fackenthal, J Schumm, P Olopade, OI

Citation: Q. Gao et al., Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer, HUM GENET, 109(2), 2001, pp. 239-240

Authors: Gao, Q Tomlinson, G Das, S Cummings, S Sveen, L Fackenthal, J Schumm, P Olopade, OI

Citation: Q. Gao et al., Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer, HUM GENET, 107(2), 2000, pp. 186-191

Authors: List, MA Siston, A Haraf, D Schumm, P Kies, M Stenson, K Vokes, EE

Citation: Ma. List et al., Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: A prospective examination, J CL ONCOL, 17(3), 1999, pp. 1020-1028